Epidemiologic studies suggest a strong genetic component for susceptibility to systemic lupus erythematosus (SLE). To investigate the genetic mechanism of pathogenesis of SLE, we studied the difference in gene expression of peripheral blood cells between 10 SLE patients and 18 healthy controls using oligonucleotide microarray. When gene expression for patients was compared to the mean of normal controls, among the 3002 target genes, 61 genes were identified with greater than a twofold change difference in expression level. Of these genes, 24 were upregulated and 37 downregulated in at least half of the patients. By the Welch's ANOVA/Welch's t-test, all these 61 genes were significantly different (Po0.05) between SLE patients and normal controls. Among these genes with differential expression, IFN-o and Ly6E (TSA-1/Sca-2) may play an important role in the mechanism of SLE pathogenesis. TSA-1 antigens may represent an important alternative pathway for T-cell activation that may be involved in IFN-mediated immunomodulation. Hierarchical clustering showed that patient samples were clearly separated from controls based on their gene expression profile. These results demonstrate that high-density oligonucleotide microarray has the potential to explore the mechanism of pathogenesis of systemic lupus erythematosus.
Introduction
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with extremely heterogeneous clinical features, varying in pathogenicity from mild forms of the disease to those that advance relentlessly leading to progressive end organ damage. The etiopathogenesis of SLE is complex, involving both environmental and genetic factors. 1 Epidemiological studies suggest a strong genetic component for susceptibility to SLE 2, 3 and multiple genes including those that affect immune complex deposition, and the MHC have been implicated in pathogenesis. [4] [5] [6] Several whole-genome linkage studies have also been reported suggesting about 20 SLE susceptibility loci. [7] [8] [9] [10] Together, these studies suggest that SLE is a polygenic disorder with contributions from multiple genes, each one of which has a modest effect.
Gene expression studies in SLE may complement linkage and association studies. With the human genome sequence project nearly completed, most of the cDNA sequences and physical locations of expressed human genes are available. This is a critical resource for these expression approaches. New approaches in functional genomics, such as cDNA/oligonucleotide array, allow for such analysis. cDNA/oligonucleotide microarray allows monitoring of tens of thousands of genes and, eventually, all expressed genes in the genome simultaneously, thus providing a format for identifying both alterations in individual genes and changes in transcriptional activity on a whole genome scale. 11, 12 Microarrays may serve as targets for hybridization of cDNA probes prepared from mRNA sample derived from cells or tissues, thus allowing the analysis of differential gene expression. This approach has been used to obtain expression profile of complex diseases and discover novel disease-related genes. [13] [14] [15] [16] In this paper, we have studied the difference in gene expression of peripheral blood white cells between SLE patients and healthy controls using the oligonucleotide microarray in order to investigate the mechanism of pathogenesis of systemic lupus erythematosus.
Results

Differential gene expression in SLE
To identify genes expressed differentially between SLE patients and normal controls, three selection criteria were applied to each of the 3002 genes analyzed. (1) In total, 489 genes had intensities that were at least 10-fold (row data 15 000/1500) greater than background in one or more sample. (2) Out of 489 genes, 189 demonstrated 2.0-fold higher or lower expression in at least half of SLE patients than in the mean of a set of normal controls (NC1, NC2, and NC3). (3) Welch's ANOVA/Welch's t-test applied to the whole data set regardless of fold change, identified 602 genes that differed significantly between SLE patients and normal controls. A total of 61 genes met these three criteria.
Of these 61 genes that were differentially expressed, 24 were upregulated and 37 were downregulated (Tables 1  and 2 ). Although most of these genes function in a 
Two-way cluster analysis
To define patterns of gene expression in controls and SLE patients, we performed a two-way hierarchical cluster analysis of both samples and genes using GeneSpring software. Figure 1 presents the results of clustering. Gene expression data were shown in a matrix format with each column representing hybridization results for a single gene, and each row representing the measured expression level for 61 differential expression genes in a single sample, red and blue colors indicating transcript levels above and below normal. There were 10 SLE patients, two normal control groups, NC1 and NC2 from the same control group, and NC3 from another control group. As shown in the dendrogram, patient samples were clearly separated from controls based on their gene expression profile. Within the SLE patient cluster, gene expression profiles were heterogeneous as demonstrated by different branches.
Verification of microarray hybridization
For verification of hybridization signals through the 5'TaqMan fluorogenic quantitative PCR assay using gene-specific primers and probes, we selected three differentially expressed genes (Ly6E, OAS2, and CEBPD). Quantitative TaqMan PCR analysis was performed for Ly6E, OAS2, CEBPD, and GAPDH. GAPDH was used as an internal control. When comparing the gene expression ratios between the patients and controls obtained by oligonucleotide microarrays to those obtained by fluorogenic quantitative PCR, similar expression pattern were obtained for Ly6E, OAS2, and CEBPD. Figure 2 shows the comparison between the two quantitative methods for each of the three genes. In all cases, the expression pattern as measured by microarray quantitation is similar to those measured by TaqMan analysis, indicating that quantitation of gene expression by oligonucleotide microarray hybridization was accurate.
Discussion
In this study, we used global expression profiling with oligonucleotide microarray to systematically characterize gene expression of peripheral blood cells from SLE patients compared to controls. As a screening approach, we used a high-density oligonucleotide microarray, representing 3002 known human genes. After ensuring the reproducibility and reliability of the microarray methodology, we identified 61 genes with differential expression between SLE patients and controls by an expression ratio greater than 2.0-fold in at least half of the 10 patients studied. By the Welch's ANOVA/Welch's t-test, all these 61 genes were significantly different (Po0.05) between SLE patients and normal controls. Among these differentially expressed genes, IFN-o and Ly6E (TSA-1/Sca-2) may play an important role in the mechanism of pathogenesis of SLE. Our discussion focuses primarily on the pathway of the interferon system.
Most of the genes identified in this study as differentially expressed, such as IL-1RII, MMP9, CCR7, IL-18R, IL1RN, showed expression patterns similar to those reported previously using membrane microarrays. 17 Other results reported previously in SLE patients, such as increased IL-10, IL-6, and bcl-2, were not confirmed by our microarray data. 17 The fluorescent intensity of these genes was equal to the background fluorescence intensity. Therefore, we suspect that such false-negative results were due to the relatively low sensitivity of the oligonucleotide microarray method, resulting in a bias of the array data toward abundant transcripts. 18 Of the many differentially expressed genes found in our study, changes in protein expression levels have been previously reported including IFN-o, 19 OAS series enzymes, 20, 21 ADPRT, 22 and TCR a.
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A noteworthy finding in our study, is the interferon pathway. The first documented cytokine abnormality in SLE patients was an increased serum level of interferon, subsequently characterized as IFN-a. 24 Owing to a sequence homology of about 60-70% between IFN-o and IFN-a, IFN-o was originally considered a subfamily of IFN-a (thus its old designation as IFN-a II). 25 Later, IFN-o was found in the sera of SLE, and it may also be a major IFN species produced by peripheral blood cells in SLE patients. 19, 20, [26] [27] [28] In naturally occurring SLE, both circulating IFN-a and increased levels of IFN-a-inducible proteins, such as OAS1, OAS2, and OASL, have been reported. [19] [20] [21] Because long-term IFN-a therapy of patients with nonautoimmune disorders can induce antinuclear antibodies, antibodies to native DNA and also Fold-change Figure 2 Verification of microarray quantification. Relative mRNA levels (Fold-change y-axis) of the indicated genes Ly6E, OAS2, and CEBPD were measured using the TaqMan 5'nuclease fluorigenic quantitative PCR assay (left column) in same samples (x-axis) as those used to prepare probes for the microarray hybridizations (right column). Data from TaqMan 5'nuclease fluorigenic quantitative PCR assay were normalized to internal control gene of GAPDH, data from microarray hybridizations were normalized as stated in Materials and methods. Quantitative measurements from both assays produced similar expression pattern for the genes measured.
an SLE-like syndrome, 29, 30 the endogenous production of IFN-a in SLE may play a role in the development of this autoimmune disease. This possibility is also supported by findings that IFN-a, beside its antiviral activity, also has several immunoregulatory functions. For example, IFN-a stimulates immunoglobulin production by PBMC in vitro, 31 can keep activated T cells alive, 32 inhibits B cell receptor-mediated apoptosis, 33 and induces dendritic cell differentiation in SLE. 34 As a result, IFN-a may play a pivotal role in the etiopathogenesis of SLE. 35 Ly6E, also named TSA-1 (thymic shared antigen-1)/ Sca-2 (stem cell antigen-2), is a member of the Ly-6 family of molecules. 36 Although the biologic roles for those molecules are not well understood, there is mounting evidence that they participate in intercellular adhesion and signaling. 36 Initially, TSA-1 was found on all immature thymocyte subsets (CD3À4À8À, CD3À4À8+, CD3À4+8À, CD3À4+8+, CD3low4+8+), but not found on CD3high4+8À and CD3high4À8+ thymocytes, early thymic migrants and peripheral T cells. So TSA-1 was taken as a novel thymocyte marker discriminating immature from mature thymocyte subsets. In the periphery, TSA-1 was detected on B lymphocytes. 37 In addition, there was a direct inverse relationship between TSA-1 and CD3 expression on thymocytes. There were many reports about TCR/CD3 defects in SLE patients. 23, 38, 39 In our study, we also found the TCRs pathways, TCRa, TCRd, and Zap-70 associated protein kinase 70 kDa) had lower expression in SLE patients. So, an inverse relationship between TSA-1 and CD3 expression on thymocytes may reflect abnormal activated lymophocytes in SLE patients. Noda et al 40 found protection from anti-TCR/CD3-induced apoptosis in immature thymocytes by a signal though TSA-1/Sca-2, and modulation of TCRmediated signaling pathway by TSA-1/Sca-2. 41 The surface expression of Ly-6 antigens on T cells in vivo and in vitro can be dramatically enhanced by IFN-a. 42 TSA-1 mRNA levels in normal human PBMCs were also enhanced strongly by IFN-a and slightly by IFN-g. 36 These studies suggested that TSA-1 antigens may represent an important alternative pathway for T-cell activation in SLE patients involved in IFN-mediated immunomodulation.
Finally, a number of the observed differences in gene expression in SLE patients could be attributed to the immunosuppressive medication rather than the disease itself, such as IL-1RII gene upregulated by glucocorticoids. 17 Hierarchical clustering showed that patient samples were clearly separated from controls based on their differential gene expression profile. These differential expression genes can be taken as characteristic signatures of gene expression in SLE patients for clinical diagnosis and differential diagnosis. 43 However, profiling a larger cohort of patients will be required to confirm these results.
This new and comprehensive approach has some limitations. For instance, the pooling strategy may mask some degree of gene expression heterogeneity in normal control. We separately pooled total RNA from the two normal control groups, in an attempt to reduce the variations. Analyzing many of individual normal controls would have made this study economically prohibitive. Most of the genes identified in this study are differentially expressed, yielding results similar to those reported by others using many individual normal controls. 17 In addition, this pooling strategy appears to have been effective in previous studies. 15 Of additional concern, in the current study the samples contained unseparated leukocytes. In contrast to malignant diseases, which involve the transformation of single cell type, SLE involves immune abnormalities in a wide variety of cell populations to include B and T lymphocyte, monocytes, and natural killer cells. A decrease or increase in gene expression detected in a mixed cell population may be because of the differences in cell populations (such as lymphopenia) between the SLE patients and normal controls. Future studies using purified cells will be necessary to elucidate changes in gene expression in specific cell types further. However, these may be more subject to artifacts caused by cell purification methods. Although the biological significance of these differentially expressed genes discussed above are not yet completely understood, the current observations may serve as necessary platform to explore relevant mechanisms of pathogenesis of SLE. Our work shows that high-density oligonucleotide microarray have the potential to explore the mechanism of pathogenesis of complex diseases such as SLE.
Materials and methods
Patients and controls
We collected 10 Chinese patients all fulfilling the American College of Rheumatology classification criteria for SLE. 44 These patients included one male patient and nine female patients, 17 to 39 years old, averaging 29 years old. Data on the age, clinical characteristics, disease activity, and current medication are presented in Table 3 . Disease activity in SLE patients was determined using SLEDAI score. 45 There were two groups of Chinese normal controls, one group included 10 normal controls, five male controls and five female controls. The other included eight normal controls, four male controls and four female controls, 20 to 36 years old, with an average age of 30 years.
Total RNA extraction and preparation of target biotinylated cRNA Heparinized venous peripheral blood was collected. Erythrocytes were then lysed with a lyse solution of amine oxalate. Total RNA extraction was performed using the TRIzol reagent (Life Technologies, Inc.). All of total RNA from the two groups of normal controls was separately pooled, as two normal controls of patient of SLE (NC1and NC2 from one group of normal controls; NC3 from the second group of normal controls). Conversion of 20 mg total RNA to single-strand cDNA and double-strand cDNA template was done by reverse transcription using a cDNA synthesis kit (Roche). In vitro transcription was performed using T7 MEGAscript transcription kit (Ambion), in the presence of biotinlabeled CTP (biotin-14-CTP Life Technologies) and unlabeled ATP, CTP, GTP, and UTP. Finally, we purified biotin-labeled cDNA using phenol-chloroform-isoamyl alcohol extraction method.
Hybridization of biotin-labeled cRNA to oligonucleotide microarrays and detection We used Mergen ExpressChipTM DNA Microarray System Human HO4 (cat# HO4-001) that contained 104 negative control spots, 88 positive control spots and 2-3 duplicate spots for 164 genes. So there were 3002 genes which distributed over subarrays A-D. The complete list of genes with accession numbers is published at http:// www.mergen-ltd.com. Hybridization of biotin-labeled cRNA with oligonucleotide microarray and detection was done according to the operating program provided by the ExpressionChip DNA Microarray System kit (Mergen Ltd).
Image and data acquisitions and normalization
The image of gene expression of microarray was scanned with a ScanArray 5000 (GSI Lumonics). Then we converted the scanned image information into numeric data though QuantArry 2.0 image analysis software (GSI Lumonics). In order to transform raw data to normalized data, we subtract the median value of the negative controls. The formula used here was (signal strength of gene A in sample X)À(median signal of the negative controls in sample X).
Duplicated spots for each gene were averaged. Then we normalized each sample to itself, to remove the differences in amount of exposure between samples, making different samples comparable to one another. The formula used to do this was (the signal strength of gene A in sample X)/(the median all of the measurements taken in sample X).
Microarray reproducibility
To assess array-and hybridization-based experimental variability, we initially performed hybridization on duplicate microarrays using the same pool of control target RNA from the first group of normal control (see supplementary data). One initial RNA sample was divided into two aliquots (NC1 and NC2), which were then taken through cDNA synthesis and cRNA labeling in parallel, hybridization of biotin-labeled cRNA to two oligonucleotide microarrays. Using all 3002 genes as data points, a linear regression analysis was performed on the fluorescence intensity difference per gene obtained in experiments 1 and 2. The two experiments were highly reproducible: 98% of the genes showed o2-fold difference in response, with a high correlation coefficient (r 2 ¼ 0.9373). Upon further analysis, we also found that the false-positive results were mostly random. If we repeated the experiment twice, the incidence of false positive was 0.04% (2 Â 2%), so repeating the experiment twice would avoid false positive as a result of impurity. In addition, repeated experiments of different samples would overcome the error from using a single sample. These data demonstrated a high level of reproducibility of the technique.
Microarray reliability
In our experiment, we used the ExpressChipTM DNA Microarray System from Mergen Ltd. It is a simple-touse and cost-effective kit for high-throughput gene expression profiling. The system contained two identical glass slides spotted with oligonucleotide microarrays. The two slides allowed for the comparison of gene expression levels between two different sources. Each slide was arrayed with more than 3000 different oligonucleotide sequences specific for human genes with known biological roles. In addition, human housekeeping genes and non-human sequences were included on each slide to serve as positive, negative, and normalization controls. The design of the oligonucleotide sequences followed a set of rigorously controlled criteria, including unique match with GenBank's human database, minimal variation in Tm and GC contents, low nucleotide repetition, size restriction (30-mer), and consistent position within the gene sequences (relative to mRNA 3' end). The arraying process was under stringent control for superior printing quality. This ensured consistency, high sensitivity and optimal signal-to-background ratio. The oligonucleotides were covalently bound to the glass surface through a chemical reaction. From our results, the fluorescence signal intensity of blank spots and negative spots was very low, where as the fluorescence signal intensity of positive spots was very high, and had saturation point and nonsaturation point, demonstrating the reliability of our data.
Statistical analysis
Data were analyzed with GeneSpring software (Silicon Genetics). 46 The detailed protocols are provided by the manufacturer at http://www.sigenetics.com/cgi/SiG. cgi/Products/GeneSpring. To identify those genes whose expression levels changed differentially between SLE patients and normal controls, as well as to reduce the data set to a manageable size and prevent the inclusion of false positives, genes were only selected for further analysis if they met the following three criteria: (1) The raw intensity was 10-fold higher than the background nonspecific binding for that hybridization of at least one sample of the 13 samples, (2) Welch's ANOVA/ Welch's t-test were used to screen for statistically significant differences in expression level between SLE patients and normal controls, the significance level was taken at a conventional 0.05 and (3) the gene expression change level in half of SLE patients (5/10 patients) were 2.0-fold higher or lower than the mean of a set of normal controls (NC1, NC2, and NC3). To group patient and control samples on the basis of similarity in their gene expression, two-way hierarchical cluster analysis of both statistically significant difference genes and samples was performed using GeneSpring software.
Taqman 5'nuclease fluorogenic quantitative PCR assay
Quantitative TaqMan PCR analysis (Perkin Elmer) was performed for genes of Ly6E, OAS2, CEBPD, and GAPDH. GAPDH was used as an internal control. The primers and TaqMan probes were designed using the Primer Express software (Perkin Elmer), as follows: LY6E (forward primer 5'-AGA CCT GTT CCC CGG CC-3', reverse primer 5'-CAG CTG ATG CCC ATG GAA G-3', TaqMan probes FAM 5'-CCC ATC CCA GAA GGC GTC AAT GTT G-3'TAMRA), CEBPD(forward primer 5'-GCG ACA AGG CCA AGC G-3', reverse primer 5'-TCG TTC TCA GCC GAC AGC T-3', TaqMan probes FAM5'-AAC CAG GAG ATG CAG CAG AAG TTGGTG-3'TAMRA), OAS2(forward primer 5'-TGA GAG CAA TGG GAA ATG GG-3, reverse primer 5'-AGG TAT TCC TGG ATA AAC CAA CCC-3', TaqMan probes FAM5'-CCC AGC TGT CCT CGG TGC CTG-3'TAMRA), GAPDH(forward primer 5'-GAA GGT GAA GGT CGG AGTC-3', reverse primer 5'-GAA GAT GGT GAT GGG ATT TC-3', TaqMan probes FAM5'-CAA GCT TCC CGT TCT CAG CC-3'TAMRA). The reaction was carried out in an ABI prism 7700 Sequence Detector (Perkin-Elmer) for 4 min at 951C and 35 cycles of 15 s at 951C and 1 min at 601C. Results were obtained and analyzed using SDS software (PerkinElmer).
